14,995 Shares in Phreesia, Inc. (NYSE:PHR) Purchased by Proficio Capital Partners LLC

Proficio Capital Partners LLC bought a new stake in shares of Phreesia, Inc. (NYSE:PHR) during the fourth quarter, Holdings Channel reports. The fund bought 14,995 shares of the company’s stock, valued at approximately $377,000.

A number of other institutional investors have also added to or reduced their stakes in PHR. R Squared Ltd bought a new position in shares of Phreesia during the fourth quarter valued at approximately $30,000. BankPlus Trust Department bought a new stake in Phreesia during the 4th quarter valued at $34,000. Venturi Wealth Management LLC purchased a new position in shares of Phreesia in the 4th quarter valued at $76,000. Smartleaf Asset Management LLC raised its position in shares of Phreesia by 154.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 3,442 shares of the company’s stock worth $89,000 after acquiring an additional 2,090 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Phreesia during the 3rd quarter worth $247,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on PHR. Citigroup lifted their target price on Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Needham & Company LLC reiterated a “buy” rating and set a $29.00 price objective on shares of Phreesia in a research note on Thursday, March 13th. Piper Sandler restated an “overweight” rating and issued a $33.00 target price (up from $31.00) on shares of Phreesia in a research note on Wednesday, January 29th. Royal Bank of Canada raised Phreesia from a “sector perform” rating to an “outperform” rating and upped their price target for the stock from $24.00 to $32.00 in a research report on Wednesday, January 8th. Finally, Truist Financial raised their price objective on Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Phreesia currently has an average rating of “Buy” and a consensus price target of $31.33.

Insider Transactions at Phreesia

In other Phreesia news, General Counsel Allison C. Hoffman sold 3,982 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $26.61, for a total value of $105,961.02. Following the sale, the general counsel now directly owns 159,137 shares of the company’s stock, valued at approximately $4,234,635.57. This represents a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Balaji Gandhi sold 3,195 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $26.61, for a total value of $85,018.95. Following the sale, the chief financial officer now directly owns 148,509 shares in the company, valued at $3,951,824.49. This represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 162,442 shares of company stock worth $4,611,300 over the last three months. 5.80% of the stock is currently owned by insiders.

Phreesia Stock Performance

Shares of PHR opened at $28.11 on Wednesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. The stock has a 50-day moving average of $27.40 and a two-hundred day moving average of $24.12. The stock has a market cap of $1.65 billion, a P/E ratio of -19.12 and a beta of 1.03. Phreesia, Inc. has a one year low of $17.07 and a one year high of $30.53.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.